Many complex diseases are influenced by genetic variations in multiple genes, each with only a small marginal effect on disease susceptibility. Pathway analysis, which identifies biological pathways associated with disease outcome, has become increasingly popular for genome-wide association studies (GWAS). In addition to combining weak signals from a number of SNPs in the same pathway, results from pathway analysis also shed light on the biological processes underlying disease. We propose a new pathway-based analysis method for GWAS, the supervised principal component analysis (SPCA) model. In the proposed SPCA model, a selected subset of SNPs most associated with disease outcome is used to estimate the latent variable for a pathway. The estimated latent variable for each pathway is an optimal linear combination of a selected subset of SNPs; therefore, the proposed SPCA model provides the ability to borrow strength across the SNPs in a pathway. In addition to identifying pathways associated with disease outcome, SPCA also carries out additional within-category selection to identify the most important SNPs within each gene set. The proposed model operates in a well-established statistical framework and can handle design information such as covariate adjustment and matching information in GWAS. We compare the proposed method with currently available methods using data with realistic linkage disequilibrium structures, and we illustrate the SPCA method using the Wellcome Trust Case-Control Consortium Crohn Disease (CD) data set. Genet. Epidemiol. 34:716-724, 2010. 
INTRODUCTION
With the rapid development of genotyping technology, genome-wide association studies (GWAS) have become a popular approach for the identification of genes and genetic variants involved in complex diseases. A series of published results have demonstrated successful identification of SNPs involved in complex traits [Manolio et al., 2009; McCarthy et al., 2008; Wellcome Trust Case Control Consortium, 2007] . While the standard approach for GWAS has been single SNP analysis, recently, pathwaybased analysis methods have also been proposed [Chasman, 2008; Schwarz et al., 2008; Wang et al., 2007] . These methods allow the integration of gene annotation databases such as Gene Ontology (GO) [Ashburner et al., 2000] to formally test for subtle but coordinated effects of the genetic variants in each pathway. Pathway analysis has been used widely in the analysis of gene expression data and has been shown to be an effective tool for delineating the underlying biological processes (BPs) involved in transcriptome changes Goeman and Buhlmann, 2007; Subramanian et al., 2005; .
Integrating prior biological knowledge into association studies and identifying pathways with disease association also can be valuable for GWAS for several reasons: (1) because the underlying biological mechanism for complex diseases is likely to be dependent on perturbation of different biological pathways, pathway analysis may approximate the true disease process more closely and shed biological insight; (2) while SNPs that are truly associated with disease but have only mild effects will likely be missed by single SNP analysis, pathway-based analysis provides a way to combine weak signals from the individual variants in each pathway to improve power; and (3) as the number of genomic markers on high-density SNP chips increases, brute-force searching for groups of r 2010 Wiley-Liss, Inc.
SNPs that jointly affect disease outcome is becoming less feasible. Gene annotation databases, however, provide an automatic way of grouping SNPs on functionally related genes.
Several recent papers have explored the feasibility of pathway analysis for GWAS. In an interesting paper, Chasman [2008] evaluated the utility of gene set analysis methods based on Fisher's exact test, which tests for overrepresentation of SNPs associated with disease within a pathway. Along the same lines, adapted the gene set enrichment analysis (GSEA) method of Subramanian et al. [2005] to GWAS, to test the distribution of association between outcome and genes within a pathway versus that between outcome and other genes using a modified Kolmogorov-Smirnov test. Goeman and Buhlmann [2007] classified pathway analysis into two categories: competitive and self-contained tests. A competitive test compares test statistics for genes in the pathway to a background defined by the complement of that pathway. Both Fisher's exact test and GSEA are competitive tests. A self-contained test, in contrast, compares the gene set to a fixed standard that does not depend on the measurement of genes outside the pathway.
In this article, we propose a new, self-contained test for testing association between a group of SNPs in a pathway with qualitative and quantitative traits using a modified principal component analysis (PCA) approach. PCA, a popular method for reducing high dimensionality to capture variations in gene expression or SNP markers, has been applied to gene expression pathway analysis, multi-locus association studies, and population structure correction [Gauderman et al., 2007; Tomfohr et al., 2005; Wang and Abbott, 2008; Zhu et al., 2002] . In the analysis of GWA studies, PCA is an effective approach for testing association of the joint effects of genetic variations in genes/SNPs with phenotypic variations while accounting for correlations between the SNPs due to linkage disequilibrium (LD). However, one limitation of PCA is that the latent variable identified by the PCs may or may not be related to clinical phenotypes [Bair and Tibshirani, 2004; Bair et al., 2006] .
To address this difficulty, Bair and Tibshirani [2004] and Bair et al. [2006] proposed the supervised PCA (SPCA) method, which estimates PCs from a selected subset of genes most associated with outcome, instead of performing PCA on all genes. Because initial screening of the variables uses outcome (e.g. disease status) information, this method is referred to as supervised. In the context of prediction analysis, SPCA has been shown to have excellent performance at predicting survival and continuous outcomes using gene expression data [Bair and Tibshirani, 2004; Bair et al., 2006] .
In this article, we adapt the SPCA model to pathwaybased SNP association analysis to test the association between a group of SNPs and variation in disease outcome. In the section Methods, we first give an overview of the proposed method. Then, using genotype data with realistic patterns of LD and allele frequencies, we conduct a simulation study that compares our method with an unsupervised PCA method, Fisher's exact test, GSEA, and the sum statistic [Hoh et al. 2001] . In the section Results, we describe the details of the simulation study results and illustrate the SPCA model using a real Crohn's disease case-control GWAS data set. Finally, we provide some concluding comments in the section Discussion.
METHODS AN OVERVIEW OF THE PROPOSED SUPERVISE PRINCIPAL COMPONENT ANALYSIS (SPCA) METHOD
The idea behind the SPCA model is that within a biological pathway, genetic variations in a subset of SNPs, each contributing a modest amount to disease predisposition, work together to disrupt normal biological process. For simplicity, we use the terms ''gene category'', ''pathway'', and ''gene set'' interchangeably, although they may not be strictly equivalent. Given a gene category defined a priori (e.g. categories from the GO or KEGG database), we first map SNPs on an array to groups of genes within each category. Then we select a subset of SNPs most associated with disease outcome and estimate the latent variable through PCA of this subset. Finally, to identify gene categories associated with disease outcome, we test for association between the estimated latent variable and disease outcome using a linear model. SPCA uses outcome information in the initial SNP screening; to account for this step, we propose an approximation to the sampling distribution of the test statistic in the linear model, which uses a Gumbel extreme value mixture distribution. In addition, to account for the effect of pathway size, we propose a simulation-based standardization procedure.
In the proposed model, the estimated latent variable is an optimal linear combination of a selected subset of SNPs; therefore, the proposed SPCA model provides the ability to borrow strength across both disease-predisposing and disease-protective SNPs in a pathway. In addition to identifying SNP pathways associated with disease outcome, SPCA also carries out within-category selection to identify the most important SNPs within each gene set (see details in the section Results). Finally, the proposed model operates in a well-established statistical framework and can handle design information such as covariate adjustment and matching information in a GWAS.
SUPERVISED PCA MODEL
The SPCA model is discussed in detail in Bair and Tibshirani [2004] , Bair et al. [2006] , and Chen et al. [2008] . In this article, we discuss the application of a SPCA model to pathway-based analysis of association studies. The SPCA model estimates and tests disease association with principal component scores that account for correlations in the SNPs due to LD. The assumption behind the supervised PCA model is that within a gene set defined a priori, genetic variations in a subset of the SNPs are associated with a latent variable, which then varies with the outcome. Our objective is then to select the subset of relevant SNPs, estimate the latent variable, and assess its statistical association with outcome. To this end, we used the following supervised PCA model:
where p j 5 (1) For each SNP, compute an association measure by fitting a logistic regression model with disease status as the outcome variable and genotype (0, 1, 2) as the predictor. For the ith SNP, let the association measure p i be the single SNP P-value (i.e. P-value corresponding to regression coefficient for genotype in the logistic model). (2) Given all SNPs in the gene set G, pre-determine a set of m threshold values for the association measures: we let fr 1 ; r 2 ; . . . ; r m g be a linearly ordered subset of real numbers such that r 1 or 2 . . . or m . In this paper, for the simulation study and real data set analysis, we used m 5 20 thresholds by placing the thresholds at each increment of 5 percentiles of the association measures (single SNP P-values in (1)).
. . . ; n SNPs g be the subset of SNPs with association measures below the threshold.
Compute the first principal component score PC1 using only SNPs in L k and fit Model 1. (4) Let T k ¼b 1k =s:e:ðb 1k Þ be the t-statistic corresponding to PC1 (computed using SNPs corresponding to threshold L k ) in Model 1. Therefore, for the m threshold values, we have m t-statistics fT 1 ; T 2 ; . .
we derive the asymptotic distribution of this statistic.
ASYMPTOTIC DISTRIBUTION OF M n
Without the gene selection process, when all genes in a gene set defined a priori are included in analysis, the test statistic T ¼b 1 =s:e:ðb 1 Þ in Model 1 follows a t-distribution. However, after the SNP selection step in the section Supervised PCA Model, the test statistic can no longer be approximated well using a t-distribution.
Given a set of normal random variables fT 1 ; . . .
In this section, first we describe the Gumbel extreme value distributions for modeling the maximum and minimum of a set of n normal random variables, then we show the distribution of M n follows a two-component mixture distribution based on the Gumbel extreme value distributions. In the section Application of the Theory to Significance Testing in Gene Set Analysis, we discuss practical applications of the theory to the analysis of gene sets.
Given a set of normal random variables fT 1 ; . . . ; T n g, under regularity conditions [Leadbetter et al., 1982] , the maximum M 1n ¼ max 1 k n T k can be shown to follow the Gumbel maximum distribution:
where t 1 5 a n (u n Àb n ), a n 5 (2 log n) 1/2 and b n 5 (2 log n)
À1/2 (log log n1log 4p).
Here, the normalizing constants a n and b n serve as scale and location parameters of the distribution. In gene set analysis, given a set of t-statistics from fitting Model 1 at different thresholds, a n and b n help normalize the effect of gene set size n. In the section Application of the Theory to Significance Testing in Gene Set Analysis, we show this important property of the extreme value distribution helps to increase the computational efficiency dramatically, by allowing us to pool M n values for gene sets with different gene set sizes in a given study. Next, the corresponding density function for the maximum is
n the distribution function for the minimums can be derived as
The density function for the minimum is then
where t 2 5 a n (u n 1b n ). Now, for a given gene set, let M n ¼ fT k : jT k j ¼ max 1 k n jT k jg, and p 5 Pr(M n 40), then the distribution function for M n can be approximated as a two-component mixture distribution:
The conditioning argument in the third line above follows because if M n is positive, then M n must be the maximum of all t-statistics fT k ; k ¼ 1; . . . ; ng, so M n ¼ M 1n and can be approximated with a Gumbel maximum distribution. Similarly, if M n is negative, then M n must be the minimum of all fT k ; k ¼ 1; . . . ; ng, so M n ¼ M 2n and can be approximated with a Gumbel minimum distribution. The corresponding density function for the mixture distribution is then
APPLICATION OF THE THEORY TO SIGNIFI-CANCE TESTING IN GENE SET ANALYSIS
When applying the theory in the section Asymptotic Distribution of M n to gene set analysis, we note that several assumptions are violated: for each gene set, to keep the amount of computation manageable, only a finite number (m 5 20) of t-statistics can be computed. Let n 5 pathway size or the number of SNPs, m 5 number of thresholds of association measures in step (2) of the section Supervised PCA Model. Note that when the thresholds are placed at small intervals (e.g. at every increment of 5 percentiles of the t-statistics), lim D!1 M m ¼ M n where D 5 interval length, or the number of SNPs within the interval. In addition, from fitting Model 1 using SNPs corresponding to each threshold, we have a set of t-scores instead of normal scores, and the t-scores are correlated by construction. Therefore, the approximation in Equation (6) and (7) may not be precise.
Given a large number of gene sets, to estimate P-values for each gene set accurately, our strategies are to use the theory in the section Asymptotic Distribution of M n to account for different gene set sizes, and then model the null distribution of M m by generating random outcomes for each gene set, pooling M m values for all gene sets, and estimating (additional) parameters of the mixture distribution. More specifically, we follow these steps: (i) Generate random outcomes for each gene set. For each gene set, fixing the genotype data set, we generate disease status for each sample from a Bernouli distribution with parameter q, where q is the proportion of case samples. Because the disease outcomes were generated randomly, without looking at the SNP values, the resulting M m values represent a random sample from the null distribution of M m . (iv) However, the P-values estimated directly using the null distribution in (iii) will often be coarse, when the number of gene sets tested in the study is only moderately large (a few hundreds to a thousand). To further improve accuracy in estimation of gene sets P-values, we add additional location and scale parameters to Equation (7), by letting t 0 1 ¼ d 1 a n ðu n À b n À g 1 Þ and t 0 2 ¼d 2 a n ðu n þ b n þ g 2 Þ for the parts correspond to maximum and minimum in Equation (7), respectively.
So, the density function (7) then becomes fðu n Þ ¼ pd 1 a n expfÀe
Given a set of M m values for the null gene sets (from (iii)) and the mixture density function (8), the parameters p, d 1 , d 2 , g 1 , g 2 can then be estimated easily. We used the R function optim for the analysis in this study. To estimate P-values for each gene set, we then substitute these estimated parameters into the distribution function with the additional parameters:
DESIGN OF A SIMULATION EXPERIMENT
We compared the performance of the supervised PCA model for pathway analysis of SNP data with several popular pathway analysis methods: Fisher's exact test, GSEA [Holden et al., 2008] , sum statistic [Hoh et al., 2001] , and an unsupervised PCA model. First, from the GO database, we randomly selected 50 gene categories. For each gene category, we obtained the list of SNPs within 5KB up-or downstream from genes in the gene set using the Ensembl database. Among the 50 selected gene sets, the number of SNPs per gene set varied from 11 to 295. We limited these SNPs to those from the Perlegen GV4 SNP chip, resulting in a total of 4,035 SNPs across the selected 50 gene sets.
To generate samples of genotype data with realistic allele frequencies and LD patterns, we used the web-based simulation tool HAP-SAMPLE [Wright et al., 2007] . HAP-SAMPLE simulates genotype data sets by resampling chromosome-length haplotypes from existing phased data sets, such as the HapMap data set, thus preserving realistic data structure in association studies. In this simulation, the SNP IDs of the 4,035 SNPs from the selected 50 gene sets across different chromosome were entered into HAP-SAMPLE, and the Caucasian cohort (CEU) (parent data from phase II) was used as the source data. The haplotypes for each chromosome were generated from HapMap samples, and haplotypes between chromosomes were assumed to be independent. A total of 20,000 genotype samples were generated. This represents the genotype data set for an artificial but realistic finite population of patients from which we can sample.
To construct causal gene sets, fixing the genotype data, for each gene set, we next simulated case-control status for the patients according to the multiplicative disease model. More specifically, for the first five gene sets (sorted by GO ID) with SNP set sizes 138, 145, 216, 254, and 262, respectively, we generated disease outcome for each patient based on the multiplicative disease model. Let g i 5 0 and 1.2 represent the number of copies of the risk allele for SNP i (i 5 1,y, D), where D is the number of SNPs in the gene set associated with disease, and let f 5 Pr (affected | g 1 ; . . . ; g D ) be the penetrance for genotype fg 1 ; . . . ; g D g. Then, assuming the multiplicative genetic model logð f=ð1 (Table I) . For each causal pathway, the causal SNPs were selected randomly without using any SNP-to-Gene mapping information, so that the causal SNPs were located on different genes. Each scenario was replicated 50 times, resulting in, by design, a total of 250 ( 5 5 Â 50) causal disease gene sets among a total of 2,500 ( 5 50 Â 50) gene sets. Under this setup, b i can be positive or negative; therefore, each gene set includes SNPs with a minor allele that either increases or decreases risk of disease relative to the major allele. To estimate b 0 , we assumed disease prevalence K to be 5%. Given prevalence K and b i ði ¼ 1; . . . ; DÞ, b 0 can then be estimated by maximizing the equation K ¼ P g1 . . . P gD Prðg 1 ; . . . ; g D Þfðg 1 ; . . . g D Þ; see details in Li and Li [2008] . Finally, for each gene set, given values for b 0 , fb 1 ; . . . ; b D g, and genotype data fg 1 ; . . . ; g D g, we computed f using the multiplicative genetic model above and sampled genotype data for 500 cases and 500 controls from the pool of 20,000 patients.
To construct null gene sets, for the remaining 45 gene sets, we generated outcome status for each sample from Bernouli (K 5 0.05) without looking at genotype data. Therefore, these are the null gene sets. For each simulation scenario, genotype data for the first 500 cases and 500 controls were next selected from the pool of 20,000 patient samples.
To implement the analysis of SPCA, unsupervised PCA, and Fisher's exact test, we used the R packages (http:/ / www.r-project.org/) superpc (with modification for binary outcomes), lm, and fisher.test, respectively. For Fisher's test, which compares the proportion of causal SNPs from a gene set to the proportion of causal SNPs in other genes, a univariate test must first be conducted for each SNP, and a significance threshold pre-specified. We used logistic regression with case-control status as outcome, and SNP status as predictor for the univariate SNP analysis. Two significance cutoff levels were used: at Bonferroniadjusted P-values of 0.05 or false-discovery rate (FDR)-adjusted P-values of 0.05.
We used the javaGSEA implementation (http:/ /www. broadinstitute.org/gsea/) for GSEA analysis. Briefly, the SNPs were pre-ranked by Chi-square test statistic from the Cochran-Armitage Trend test and this ranked list was then used for the GSEA ''Pre-ranked'' algorithm. This is the algorithm implemented in GSEA-SNP software [Holden et al., 2008] . For the sum statistic, we used the program downloaded from the author's website (http:/ /linkage. rockefeller.edu/ott/sumstat.html).
RESULTS

RESULTS OF SIMULATION EXPERIMENT
To estimate type I error rate and power of the methods, we pooled gene sets from the 50 replications, among which 250 ( 5 5 gene sets Â 50 replications) were causal gene sets and 2,250 ( 5 45 gene sets Â 50 replications) were null gene sets by design of the experiment.
For all scenarios, all methods had preserved type I error rate at the 0.05 significance level. In particular, Supplementary Figure 1 shows the distributions of P-values from the SPCA model for each scenario. Figure 1 and Table I compare the power of the methods for testing the null hypothesis H 0 : a gene set is not associated with disease. Across all scenarios, the SPCA model consistently performed best with the highest power among all methods. On the other hand, the unsupervised PCA model, which uses all SNPs in the gene set to estimate the underlying latent variable, had the lowest power among all methods. This suggests that, with the SNP selection step, supervised PCA removes some of the irrelevant SNPs before extracting the desired latent variable, thereby improving performance in discriminating causal gene sets from null gene sets. Another self-contained test (Section Introduction) that also uses only SNPs in the pathway, the sum statistic, also performed well with good power for all scenarios. Supplementary Table 1 further compares the average P-values (over 50 replications) of the sum statistic and SPCA model for each causal gene set with different gene set sizes. Across rows of this table, as expected, when the number of causal SNPs in the gene set is large (N_SNP 5 10), both methods performed well with small average P-values for each causal gene set. However, when the number of causal SNPs in the gene set is small (N_SNP 5 5), SPCA model had smaller average P-values. Across the columns of this table, while P-values from SPCA model were similar for causal gene sets with different sizes, the average P-values for sum statistics increased for larger gene sets, suggesting the results of sum statistic are affected by gene set sizes. In this simulation study, because we have selected the causal SNPs randomly, most of pairwise LDs between casual SNPs were less than 0.01. Note that when the causal SNPs display stronger LD pattern, the power of proposed method will be even higher.
Compared to the self-contained tests (SPCA and sum statistic), the competitive tests (Fisher's exact test and GSEA), which compare test statistics for SNPs in the gene set to other SNPs not in the gene set, had less power for detecting causal gene sets. This suggests that when SNPs in multiple pathways are associated with disease, competitive tests which compare association signals in a particular gene set vs. association signals from all other gene sets, may result in loss of power.
APPLICATION TO THE CROHN DISEASE (CD) GWA DATA
To further validate the proposed methodology, we next applied the methodology to a real GWAS data set: the Wellcome Trust Case Control Consortium (WTCCC) CD case-control data. Crohn's disease, a typical complex disease affected by multiple genetics factors and environmental exposures [Podolsky, 2002] , is a form of inflammatory bowel disease most commonly affecting the small intestine and/or colon, in which an overactive immune response leads to chronic inflammation. Although the genetic architecture of CD is still incomplete, recent candidate gene and GWAS [Mathew, 2008; Xavier and Podolsky, 2007] suggest three major BPs related to CD: innate immunity, adaptive immunity (regulation of IL23), and autophagy. These processes are closely associated. Autophagy can mediate innate immune responses by targeting intracellular bacteria and parasites, and connects with adaptive immunity through presenting antigen via MHC class II [Schmid and Munz, 2007] . Innate immune responses are necessary to activate adaptive immunity, leading to inflammation [Xavier and Podolsky, 2007] .
We chose the WTCCC CD data to test our proposed methodology because of the relatively clear understanding of the above-summarized biological mechanisms involved in the development of Crohn's disease, including more than 30 susceptibility loci for CD found and replicated in different GWAS [Barrett et al., 2008] . WTCCC GWA samples were genotyped using Affymetrix GeneChip 500 K arrays. After data quality control, 1,748 cases and 2,953 controls remained, with 469,557 SNPs for each sample [WTCCC, 2007] .
To conduct gene set analysis, we used gene sets from the canonical pathway (CP) and BP collections of the Molecular Signatures Database (MSigDB), a public database created by the Broad Institute (http:/ /www.broadinstitute. org/gsea/msigdb/). The CP gene sets are canonical representations of BPs compiled by domain experts, from online databases such as BioCarta (http:/ /www.biocarta. com/), KEGG (http:/ /www.genome.jp/kegg/), and others. The BP collection consists of gene sets derived from the controlled vocabulary of the GO project, in particular the ontologies in the ''BP'' category. Because of the hierarchical structure of GO, to reduce redundancy, MSigDB preprocesses gene sets to remove highly similar GO categories. To reduce the amount of multiple testing and avoid testing overly broad gene sets, we further removed gene sets with more than 250 genes. The remaining 762 GO categories and 638 CPs were used for subsequent data analysis.
To assign SNPs to pathways, we used ENSEMBL database (version 51) annotation. First, SNPs mapped within 5 KB of a gene were assigned to the corresponding gene. A total of 207,907 SNPs were mapped to 17,203 genes. Next, the genotype data in the CD case-control data set were linked to the gene sets using identifiers for the genes. We conducted gene set analysis using the proposed methodology as outlined in the section Methods. Based on the SPCA model, nominal P-values were estimated for all gene sets. To control for FDR, we also estimated adjusted P-values based on the method of Benjamini and Hochberg [1995] , using the multtest package in the R statistical software.
At FDR levels of 0.05 and 0.1, we identified 50 and 72 significant gene sets, respectively, in the CD data set. The top 40 gene sets are listed in Table II ; a large proportion of these statistically significant gene sets are involved with BPs related to the immune system, a reasonable result given the proposed biological mechanisms for CD summarized above.
Two groups of gene sets identified as statistically significant are closely related to innate immunity; one group includes gene categories related to detection and response to stimuli (bacteria), such as GO:0009595, GO:0051606, GO:0009581, and GO:0009617. The genes identified from these categories include NOD2 (CARD15), RP1, IFNGR1, CCL4, IL10, IL12B, and others. The second group of innate immunity gene sets is involved with cytokine secretion and production, activation, or regulation of the nuclear factor-kB (NF-kB) transcription factor. The PCA is the standard PCA regression; GSEA is the gene set enrichment analysis, and SUMSTAT is the sum statistic as described in Hoh et al. [2001] . PCA, principal component analysis; FDR, false-discovery rate important genes in these sets are NOD2, TNFB2, MAP3K7, ABCA1, CARD11, PRKCQ, and others. Among these genes, NOD2, the first discovered CD susceptibility gene, plays a central role in immune response pathways. By recognizing bacterial molecules that possess a muramyl dipeptide with a leucine-rich repeat domain, NOD2 activates NF-kB and mitogen-activated protein kinase signaling pathways through a receptor-interacting serinethreonine-dependent signaling pathway [Kobayashi et al., 2002] . This triggers the production and secretion of a series of pro-inflammatory cytokines, such as tumor necrosis factor-a (TNF-a), interleukin 12, and interleukin 23 (IL23), to enhance innate immunity.
Other major pathways identified as statistically significant are involved with adaptive immunity, in particular, the regulation of IL23. These pathways are the cytokinecytokine receptor interaction pathway (KEGG 04060, including genes IL23R, IR12RB2, IL18RAP, IL6R, IL28A, ARFRAP1, CCL18, IFNGR1, TNFSF15, TNFRSF1B) and the JAK-STAT signaling pathway (KEGG 04630, including genes IL23R, STAT3, IL28A, IFNGR1, GRB2, SPRED1, SPRED2). IL23 has been shown to be the ''master regulator'' of Crohn's disease, through activating a subset of T-cells (T H -17) to produce cytokine IL17 to promote inflammation. The STAT3/STAT4-dependent pathway is also required for IL23 to activate T H -17 through phosphorylation [Neurath, 2007] .
Finally, statistically significant gene sets related to autophagy include GO:0006914, GO:0009991, GO:0031668, and others. The most important genes in these gene sets are autophagy-related 16-like 1 (ATG16L1) and the IRGM gene. These two genes are responsible for intracellular responses required for autophagy and are associated with Crohn's disease risk [Hampe et al., 2007; Parkes et al., 2007; Rioux et al., 2007] . Although our top pathways are not identical to the top hits in GESA analysis by Wang et al. [2009] , the significant genes identified by SPCA, especially those in pathways related to the regulation of IL23, were also included in the most significant pathways in GSEA analysis. This indicates important association signals for CD were picked up by both methods. In summary, results of the proposed SPCA model agreed well with recent findings in multiple GWA studies and animal experiments, further validating the proposed methodology.
DISCUSSION
Many complex diseases are influenced by joint effects of genetic variations in multiple genes and environmental factors [Manolio et al., 2009] . In this paper, we have outlined a general strategy for conducting pathway analysis for GWAS data using the supervised PCA model. In addition to combining weak signals from a number of SNPs in a pathway, results from pathway analysis also can shed light on the BPs underlying disease. Typically, only a subset of SNPs within a gene set defined a priori are associated with disease outcome. Hence, without a SNP screening step, using all SNPs to summarize information from a pathway can result in reduced test power for pathway analysis, because of the inclusion of SNPs unrelated to disease. In contrast, the proposed SPCA model, which is a semi-supervised testing procedure that combines feature selection and dimension reduction techniques, removes some of the irrelevant SNPs before extracting the principal components. Using GWAS data with realistic LD structures, we have shown that this approach compares favorably with currently available pathway testing methods.
The proposed method can be further improved in several ways: (1) Assigning SNPs to genes in the pathway. In this study, we have used physical annotations to assign SNPs within 5 KB of each gene in a pathway to that gene, to capture the proximal functional elements of most genes; more distant SNPs and SNPs in LD with the included SNPs were ignored. We believe that there is a balance to be struck here: adding SNPs mapped farther away from genes will likely cover more completely the regulatory regions, but will also include more irrelevant SNPs and increase the computational burden dramatically because of the large number of genes in most pathways. A previous study [Holmans et al., 2009] found no apparent improvement in results when different window sizes were used for a pathway-based analysis method; however, more studies on this issue are clearly warranted, with functional studies that assess the impact of SNPs on gene expression likely to be particularly helpful. (2) Accounting for the hierarchical structure of GO. The GO terms used in this study are highly structured and ordered in a directed acyclic graph: the set of genes annotated to a certain term (node) is a subset of those annotated to its parent nodes. To reduce redundancy, we used collections of gene sets based on GO from the MSigDB database, which had been preprocessed to exclude extremely similar GO terms. Even after preprocessing, however, the results of gene set analysis may still include closely related processes; therefore, careful interpretation of functionally related gene sets is needed. In this study, we have taken the approach of grouping gene sets and interpreting functionally related groups of gene sets to further reduce redundancy.
Although these and other issues make pathway-based analysis of GWAS especially challenging, we believe pathway-based approaches that model joint effects of genetic variations in multiple functionally related genes is a major step forward in improving the power of GWAS and understanding molecular mechanisms of disease. In addition, the power and potential of these methods will increase as the coverage and quality of gene annotation databases improve.
